MAPK11
MOLECULAR TARGETmitogen-activated protein kinase 11
MAPK11 (mitogen-activated protein kinase 11) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAPK11
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | sb 203580 | 4.92 | 136 |
| 2 | foretinib | 4.34 | 76 |
| 3 | ponatinib | 4.26 | 70 |
| 4 | nilotinib | 4.17 | 64 |
| 5 | doramapimod | 4.06 | 57 |
| 6 | sb 202190 | 3.64 | 37 |
| 7 | regorafenib | 3.56 | 34 |
| 8 | linifanib | 3.33 | 27 |
| 9 | neflamapimod | 3.30 | 26 |
| 10 | kw 2449 | 2.64 | 13 |
| 11 | linsitinib | 2.64 | 13 |
| 12 | ast 487 | 2.56 | 12 |
| 13 | ph 797804 | 2.30 | 9 |
| 14 | rebastinib | 2.20 | 8 |
| 15 | Sorafenib | 2.08 | 7 |
| 16 | skepinone l | 2.08 | 7 |
| 17 | cep 32496 | 1.95 | 6 |
| 18 | bafetinib | 1.95 | 6 |
| 19 | talmapimod | 1.95 | 6 |
| 20 | bms 582949 | 1.95 | 6 |
| 21 | losmapimod | 1.79 | 5 |
| 22 | tak 715 | 1.79 | 5 |
| 23 | Afatinib | 0.69 | 1 |
| 24 | Anisomycin | 0.69 | 1 |
| 25 | Dasatinib | 0.69 | 1 |
| 26 | isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from | 0.69 | 1 |
| 27 | withaferin | 0.69 | 1 |
About MAPK11 as a Drug Target
MAPK11 (mitogen-activated protein kinase 11) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented MAPK11 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAPK11 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.